H-SNWKWWPGIFD-OH
Ref. 3D-PP48217
1mg | 248,00 € | ||
10mg | 292,00 € | ||
100mg | 481,00 € |
Produktinformation
Peptide H-SNWKWWPGIFD-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNWKWWPGIFD-OH include the following: Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy Y Takahashi, Y Okamoto, HA Popiel, N Fujikake - Journal of Biological , 2007 - ASBMBhttps://www.jbc.org/article/S0021-9258(20)54387-1/abstract A toxic monomeric conformer of the polyglutamine protein Y Nagai , T Inui , HA Popiel, N Fujikake - Nature structural & , 2007 - nature.comhttps://www.nature.com/articles/nsmb1215 Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Y Nagai , N Fujikake, K Ohno - Human molecular , 2003 - academic.oup.comhttps://academic.oup.com/hmg/article-abstract/12/11/1253/555306 Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis Y Nagai , HA Popiel - Current pharmaceutical design, 2008 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2008/00000014/00000030/art00006 Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases Y Nagai - Rinsho Shinkeigaku= Clinical Neurology, 2009 - europepmc.orghttps://europepmc.org/article/med/20030247 By KIMBERLY L. SCIARRETTA, DAVID J. GORDON, and SC MEREDITH - Amyloid, Prions, and Other Protein Aggregates , 2006 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=JOOCnik5QNAC&oi=fnd&pg=PA273&dq=(%22SNWKWWPGIFD%22+OR+%22H-SNWKWWPGIFD-OH%22)+AND+peptide&ots=uyQl_6UaVU&sig=PGgYTPFhVZDdFJW-mTNmJjJF2SE Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases RS Armen, BM Bernard, R Day - Proceedings of the , 2005 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0502068102 Brain-targeting delivery of two peptidylic inhibitors for their combination therapy in transgenic polyglutamine disease mice via intranasal administration M Yang , Q Zhang , Q Wang, KK Sorensen - Molecular , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.8b00938 Peptide-based inhibitors of amyloid assembly KL Sciarretta, DJ Gordon , SC Meredith - Methods in enzymology, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0076687906130153 Making protein interactions druggable: targeting PDZ domains KK Dev - Nature reviews Drug discovery, 2004 - nature.comhttps://www.nature.com/articles/nrd1578 Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice HA Popiel, Y Nagai , N Fujikake, T Toda - Neuroscience letters, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304394008008288 Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases HA Popiel, T Takeuchi, JR Burke, WJ Strittmatter - , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1878747923012345 Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death H Ren, Y Nagai , T Tucker, WJ Strittmatter - Biochemical and , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X01957833 Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins H Naiki , Y Nagai - Journal of biochemistry, 2009 - academic.oup.comhttps://academic.oup.com/jb/article-abstract/146/6/751/807596 Identifying new therapeutics for Huntington's disease G Schilling, DR Borchelt - Clinical Neuroscience Research, 2003 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1566277203000604 Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors BA Margulis, V Vigont, VF Lazarev, EV Kaznacheyeva - FEBS letters, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0014579313003657
Chemische Eigenschaften
Technische Anfrage zu: 3D-PP48217 H-SNWKWWPGIFD-OH
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.